These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35994937)

  • 1. Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study.
    Marshall AD; Martinello M; Treloar C; Matthews GV
    Int J Drug Policy; 2022 Nov; 109():103828. PubMed ID: 35994937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
    Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
    Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
    Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
    Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.
    Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV
    Lancet HIV; 2022 Jun; 9(6):e414-e427. PubMed ID: 35659336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men.
    Adu PA; Rossi C; Binka M; Wong S; Wilton J; Wong J; Butt ZA; Bartlett S; Jeong D; Pearce M; Darvishian M; Yu A; Alvarez M; Velásquez García HA; Krajden M; Janjua NZ
    Liver Int; 2021 Mar; 41(3):482-493. PubMed ID: 33305525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C risk perceptions and attitudes towards reinfection among HIV-diagnosed gay and bisexual men in Melbourne, Australia.
    Schroeder SE; Higgs P; Winter R; Brown G; Pedrana A; Hellard M; Doyle J; Stoové M
    J Int AIDS Soc; 2019 May; 22(5):e25288. PubMed ID: 31111671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018.
    Cotte L; Hocqueloux L; Lefebvre M; Pradat P; Bani-Sadr F; Huleux T; Poizot-Martin I; Pugliese P; Rey D; Cabié A;
    Clin Infect Dis; 2021 Nov; 73(9):e3266-e3274. PubMed ID: 33400777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study).
    Monin MB; Ingiliz P; Lutz T; Scholten S; Cordes C; Martínez-Rebollar M; Spinner CD; Nelson M; Rausch M; Bhagani S; Peters L; Reiberger T; Mauss S; Rockstroh JK; Boesecke C;
    Clin Infect Dis; 2023 Feb; 76(3):e607-e612. PubMed ID: 36004410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017.
    Castry M; Cousien A; Bellet J; Champenois K; Pialoux G; Yazdanpanah Y; Costagliola D; Grabar S; Deuffic-Burban S;
    Euro Surveill; 2021 Sep; 26(38):. PubMed ID: 34558403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
    Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
    Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of HCV Reinfection Among HIV-Positive MSM and Its Association With Sexual Risk Behavior: A Longitudinal Analysis.
    Newsum AM; Matser A; Schinkel J; van der Valk M; Brinkman K; van Eeden A; Lauw FN; Rijnders BJA; van de Laar TJW; van de Kerkhof M; Smit C; Boyd A; Arends JE; Prins M;
    Clin Infect Dis; 2021 Aug; 73(3):460-467. PubMed ID: 32459339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?
    Garvey LJ; Cooke GS; Smith C; Stingone C; Ghosh I; Dakshina S; Jain L; Waters LJ; Mahungu T; Ferro F; Sood C; Freeman C; Phillips C; Dhairyawan R; Burholt R; Sharp H; Ullah S; Gilleece Y; Brown A; Orkin C; Rodger A; Bhagani S
    Clin Infect Dis; 2021 Jan; 72(2):233-238. PubMed ID: 32211763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.
    Chromy D; Bauer DJM; Simbrunner B; Jachs M; Hartl L; Schwabl P; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Mandorfer M; Gschwantler M; Reiberger T
    J Viral Hepat; 2022 May; 29(5):385-394. PubMed ID: 35274399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C reinfection with protease inhibitor-resistant hepatitis C virus in an HIV-coinfected MSM.
    Yilmaz GR; Boesecke C; Schwarze-Zander C; Rockstroh JK
    Liver Int; 2020 Jan; 40(1):47-50. PubMed ID: 31612570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
    Berenguer J; Gil-Martin Á; Jarrin I; Montes ML; Domínguez L; Aldámiz-Echevarría T; Téllez MJ; Santos I; Troya J; Losa JE; Serrano R; De Guzmán MT; Calvo MJ; González-García JJ;
    AIDS; 2019 Mar; 33(4):685-689. PubMed ID: 30829744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.
    Young J; Wang S; Lanièce Delaunay C; Cooper CL; Cox J; Gill MJ; Hull M; Walmsley S; Wong A; Klein MB;
    Int J Drug Policy; 2023 Apr; 114():103981. PubMed ID: 36893502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study.
    Braun DL; Hampel B; Ledergerber B; Grube C; Nguyen H; Künzler-Heule P; Shah C; Salazar-Vizcaya L; Conen A; Flepp M; Stöckle M; Béguelin C; Schmid P; Rougemont M; Delaloye J; Bernasconi E; Nicca D; Böni J; Rauch A; Kouyos RD; Günthard HF; Fehr JS
    Clin Infect Dis; 2021 Oct; 73(7):e2194-e2202. PubMed ID: 32761122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.